Edition:
United States

Anavex Life Sciences Corp (AVXL.OQ)

AVXL.OQ on NASDAQ Stock Exchange Capital Market

2.56USD
23 Oct 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.56
Open
$2.50
Day's High
$2.56
Day's Low
$2.43
Volume
19,347
Avg. Vol
108,803
52-wk High
$5.14
52-wk Low
$1.86

Latest Key Developments (Source: Significant Developments)

Anavex Life Sciences reports PK and PD data from Phase 2a trial of ANAVEX2-73
Thursday, 12 Oct 2017 07:00am EDT 

Oct 12 (Reuters) - Anavex Life Sciences Corp :Anavex Life Sciences reports PK and PD data from Phase 2a trial of ANAVEX2-73 in mild-to-moderate Alzheimer’s Disease patients.Anavex Life Sciences Corp - ‍ANAVEX2-73 demonstrates desirable PK/PD properties.Anavex Life Sciences Corp - ‍clear concentration-effect relationship between ANAVEX2-73 and study measurements​.  Full Article

Anavex reports Q3 loss per share of $0.09
Monday, 7 Aug 2017 07:00am EDT 

Aug 7 (Reuters) - Anavex Life Sciences Corp :Anavex reports fiscal third quarter 2017 financial results.Q3 loss per share $0.09.  Full Article

Anavex Life Sciences says selling security holder‍​ to issue 5 mln shares of common stock‍​
Friday, 26 May 2017 04:46pm EDT 

May 26 (Reuters) - Anavex Life Sciences Corp ::Anavex Life Sciences Corp says selling security holder‍​ to issue 5 million shares of common stock - sec filing ‍​.  Full Article

Anavex Q2 loss per share $0.04
Wednesday, 10 May 2017 07:00am EDT 

May 10 (Reuters) - Anavex Life Sciences Corp :Anavex reports fiscal second quarter 2017 financial results.Q2 loss per share $0.04.Anavex life sciences corp - cash and equivalents of $23.4 million at march 31, 2017, compared to $9.2 million at september 30, 2016.  Full Article

Anavex Life Sciences provides update on lawsuit
Thursday, 30 Mar 2017 08:00am EDT 

Anavex Life Sciences Corp :Anavex life sciences corp reports dismissal of appeal in cortina lawsuit without payment of any fees or costs by company.  Full Article

Anavex reports Q1 loss per share $0.08
Tuesday, 7 Feb 2017 07:00am EST 

Anavex Life Sciences Corp - : Anavex reports fiscal first quarter 2017 financial results . Q1 loss per share $0.08 .Says it is now able to initiate subsequent placebo-controlled efficacy and safety trials for Anavex 2-73 in Alzheimer's and Parkinson's disease as well as rett syndrome.  Full Article

BRIEF-Anavex Life Sciences Reports Q2 Loss Per Share Of $0.11

* ANAVEX LIFE SCIENCES REPORTS FISCAL SECOND QUARTER 2018 FINANCIAL RESULTS